{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:48:08Z","timestamp":1783774088480,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.beem.2019.04.002","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T10:40:43Z","timestamp":1555152043000},"page":"101268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Management of pituitary incidentaloma"],"prefix":"10.1016","volume":"33","author":[{"given":"Cesar Luiz","family":"Boguszewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Rosa","family":"de Castro Musolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2019.04.002_bib1","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1530\/EC-18-0065","article-title":"A\u00a0comparative, population-based analysis of pituitary incidentalomas vs clinically manifesting sellar masses","volume":"7","author":"Vaninetti","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.beem.2019.04.002_bib2","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1210\/jc.2010-1048","article-title":"Pituitary incidentaloma: an endocrine society clinical practice guideline","volume":"96","author":"Freda","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.002_bib3","first-page":"917","article-title":"Incidentaloma: from general practice to specific endocrine frame","volume":"67","author":"Gheorghisan-Galateanu","year":"2017","journal-title":"J\u00a0Pak Med Assoc"},{"key":"10.1016\/j.beem.2019.04.002_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2265.1999.00748.x","article-title":"Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas - results of a prospective study","volume":"51","author":"Feldkamp","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2019.04.002_bib5","first-page":"884","article-title":"Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination","volume":"104","author":"Arita","year":"2006","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.beem.2019.04.002_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1530\/eje.0.1490123","article-title":"A\u00a0survey of pituitary incidentaloma in Japan","volume":"149","author":"Sanno","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.04.002_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11102-005-1757-1","article-title":"Retrospective multicentric study of pituitary incidentalomas","volume":"7","author":"Day","year":"2004","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2019.04.002_bib8","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1530\/EJE-15-1272","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: pituitary 'incidentaloma': neuroradiological assessment and differential diagnosis","volume":"175","author":"Vasilev","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.04.002_bib9","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1365-2265.2007.02990.x","article-title":"What is the natural history of nonoperated nonfunctioning pituitary adenomas?","volume":"67","author":"Karavitaki","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2019.04.002_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11102-017-0856-0","article-title":"Management of nonfunctioning pituitary adenomas (NFAs): observation","volume":"21","author":"Huang","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2019.04.002_bib11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.beem.2009.05.001","article-title":"Pituitary tumours: pituitary incidentalomas","volume":"23","author":"Molitch","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2019.04.002_bib12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/eje.1.02334","article-title":"The natural course of non-functioning pituitary macroadenomas","volume":"156","author":"Dekkers","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.04.002_bib13","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1055\/s-0043-115645","article-title":"Prevalence, clinical features, and natural history of incidental clinically non-functioning pituitary adenomas","volume":"49","author":"Iglesias","year":"2017","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2019.04.002_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archinte.1995.00430020067008","article-title":"The natural history of the pituitary incidentaloma","volume":"155","author":"Donovan","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beem.2019.04.002_bib15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1210\/jc.2010-1054","article-title":"Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis","volume":"96","author":"Fern\u00e1ndez-Balsells","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.002_bib16","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1530\/eje.1.02107","article-title":"Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data","volume":"154","author":"Buurman","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.04.002_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0889-8529(05)70058-X","article-title":"Differential diagnosis of sellar masses","volume":"28","author":"Freda","year":"1999","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.1016\/j.beem.2019.04.002_bib18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s11102-015-0652-7","article-title":"Pituitary incidentalomas: analysis of a neuroradiological cohort","volume":"18","author":"Esteves","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2019.04.002_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.sult.2004.10.001","article-title":"Management of pituitary incidentalomas: according to a survey of pituitary incidentalomas in Japan","volume":"26","author":"Oyama","year":"2005","journal-title":"Seminars Ultrasound, CT MRI"},{"key":"10.1016\/j.beem.2019.04.002_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1148\/radiology.193.1.8090885","article-title":"Incidental pituitary lesions in 1,000 unselected autopsy specimens","volume":"193","author":"Teramoto","year":"1994","journal-title":"Radiology"},{"key":"10.1016\/j.beem.2019.04.002_bib21","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1590\/0004-2730000003363","article-title":"Persistence of intrasellar trigeminal artery and simultaneous pituitary adenoma: description of two cases and their importance for the differential diagnosis of sellar lesions","volume":"58","author":"Machado","year":"2014","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.beem.2019.04.002_bib22","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1210\/jcem.86.7.7649","article-title":"Normal pituitary hypertrophy as a frequent cause of pituitary incidentaloma: a follow-up study","volume":"86","author":"Chanson","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.002_bib23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-120-10-199405150-00001","article-title":"Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population","volume":"120","author":"Hall","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2019.04.002_bib24","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3949\/ccjm.75.11.793","article-title":"Evaluation and management of pituitary incidentalomas","volume":"75","author":"Serhal","year":"2008","journal-title":"Clevel Clin J Med"},{"key":"10.1016\/j.beem.2019.04.002_bib25","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.002_bib26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ando.2015.04.005","article-title":"Biological and radiological exploration and management of non-functioning pituitary adenoma","volume":"76","author":"Raverot","year":"2015","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.beem.2019.04.002_bib27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2265.2008.03201.x","article-title":"Prevalence of GH and other anterior pituitary hormone deficiencies in adults with nonsecreting pituitary microadenomas and normal serum IGF-1 levels","volume":"69","author":"Yuen","year":"2008","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2019.04.002_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000430815","article-title":"Hypothalamic-pituitary axis in non-functioning pituitary adenomas: focus on the prevalence of isolated central hypoadrenalism","volume":"102","author":"Carosi","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2019.04.002_bib29","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1001\/jama.1990.03440200076026","article-title":"The 'incidentaloma' of the pituitary gland. Is neurosurgery required?","volume":"263","author":"Reincke","year":"1990","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.beem.2019.04.002_bib30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7861\/clinmedicine.13-3-296","article-title":"Pituitary incidentaloma","volume":"13","author":"Bevan","year":"2013","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.beem.2019.04.002_bib31","first-page":"3625","article-title":"Management of incidental pituitary microadenomas: a cost-effectiveness analysis","volume":"82","author":"King","year":"1997","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.002_bib32","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cncr.20412","article-title":"The prevalence of pituitary adenomas: a systematic review","volume":"101","author":"Ezzat","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2019.04.002_bib33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-14-0599","article-title":"Screening for ACTH-dependent hypercortisolism in patients affected with pituitary incidentaloma","volume":"172","author":"Toini","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.04.002_bib34","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3171\/jns.1987.66.6.0806","article-title":"Clinically silent hypersecretion of growth hormone in patients with pituitary tumors","volume":"66","author":"Klibanski","year":"1987","journal-title":"Neurosurgery"},{"key":"10.1016\/j.beem.2019.04.002_bib35","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1210\/jc.2004-0875","article-title":"Clinically silent somatotropinomas may be biochemically active","volume":"90","author":"Sakharova","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.002_bib36","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/jc.2013-3059","article-title":"Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations","volume":"99","author":"Bidlingmaier","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.002_bib37","doi-asserted-by":"crossref","first-page":"M61","DOI":"10.1530\/EJE-15-0272","article-title":"Subclinical hypercortisolism: a state, a syndrome, or a disease?","volume":"173","author":"Di Dalmazi","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.04.002_bib38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1590\/2359-3997000000295","article-title":"Long-term follow-up of patients with elevated IGF-1 and nadir GH > 0.4 \u03bcg\/L but < 1 \u03bcg\/L","volume":"61","author":"Rosario","year":"2017","journal-title":"Arch Endocrinol Metabol"},{"key":"10.1016\/j.beem.2019.04.002_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.beem.2011.06.003","article-title":"Evidence-based endocrinology: illustrating its principles in the management of patients with pituitary incidentalomas","volume":"26","author":"Bancos","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2019.04.002_bib40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ando.2015.04.004","article-title":"Management of nonfunctioning pituitary incidentaloma","volume":"76","author":"Galland","year":"2015","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.beem.2019.04.002_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.002_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.beem.2011.07.003","article-title":"Pituitary incidentaloma","volume":"26","author":"Orija","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2019.04.002_bib43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11102-010-0290-z","article-title":"Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis","volume":"14","author":"dos Santos Nunes","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2019.04.002_bib44","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.002_bib45","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of cushing's syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.04.002_bib46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1530\/EJE-16-0206","article-title":"Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists","volume":"175","author":"Greenman","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.04.002_bib47","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/cen.12684","article-title":"Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in\u00a0vivo response to cabergoline therapy","volume":"82","author":"Vieira Neto","year":"2015","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2019.04.002_bib48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11102-012-0403-y","article-title":"Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas","volume":"16","author":"Garcia","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2019.04.002_bib49","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2265.2010.03875.x","article-title":"Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis","volume":"73","author":"Murad","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2019.04.002_bib50","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1210\/er.2015-1042","article-title":"Pituitary apoplexy","volume":"36","author":"Briet","year":"2015","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2019.04.002_bib51","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","article-title":"Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement","volume":"20","author":"Casanueva","year":"2017","journal-title":"Pituitary"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19300119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19300119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:55:26Z","timestamp":1761497726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X19300119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1521690X19300119"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2019.04.002","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of pituitary incidentaloma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2019.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101268"}}